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Abstract
Background: Dengue is a major public health problem in tropical and subtropical countries. Exploring the relationships
between virological features of infection with patient immune status and outcome may help to identify predictors of
disease severity and enable rational therapeutic strategies.
Methods: Clinical features, antibody responses and virological markers were characterized in Vietnamese adults
participating in a randomised controlled treatment trial of chloroquine.
Results: Of the 248 patients with laboratory-confirmed dengue and defined serological and clinical classifications 29 (11.7%)
had primary DF, 150 (60.5%) had secondary DF, 4 (1.6%) had primary DHF and 65 (26.2%) had secondary DHF. DENV-1 was
the commonest serotype (57.3%), then DENV-2 (20.6%), DENV-3 (15.7%) and DENV-4 (2.8%). DHF was associated with
secondary infection (Odds ratio=3.13, 95% CI 1.04–12.75). DENV-1 infections resulted in significantly higher viremia levels
than DENV-2 infections. Early viremia levels were higher in DENV-1 patients with DHF than with DF, even if the peak viremia
level was often not observed because it occurred prior to enrolment. Peak viremias were significantly less often observed
during secondary infections than primary for all disease severity grades (P=0.001). The clearance of DENV viremia and NS1
antigenemia occurs earlier and faster in patients with secondary dengue (P,0.0001). The maximum daily rate of viremia
clearance was significantly higher in patients with secondary infections than primary (P,0.00001).
Conclusions: Collectively, our findings suggest that the early magnitude of viremia is positively associated with disease
severity. The clearance of DENV is associated with immune status, and there are serotype dependent differences in infection
kinetics. These findings are relevant for the rational design of randomized controlled trials of therapeutic interventions,
especially antivirals.
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Introduction
Dengue viruses (DENVs) are members of the Flavivirus genus
and are the most important arboviral pathogens of humans. The
four DENVs are antigenically-related and have single-stranded,
positive-sense RNA genomes that share 60–70% sequence identity
between each others [1]. There are no licensed vaccines to prevent
dengue and vector control remains the cornerstone of public
health interventions.
The clinical outcome from DENV infection ranges from the
asymptomatic to an acute, often debilitating illness called dengue
fever (DF), to the severe and potentially life-threatening dengue
hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The
cardinal feature of DHF/DSS is a capillary permeability syndrome
characterised by plasma leaking from the vasculature into interstitial
spaces. Thrombocytopenia, a coagulopathy and a hemorrhagic
diathesis are also common findings. DSS manifests when capillary
permeabilityissevereenoughtoresultinaninadequateintravascular
volume that then leads to poor tissue perfusion. DSS is managed,
and possibly prevented, by careful restoration and maintenance of
the intravascular volume by use of parenteral fluids. Viral strain and
host immune status have been suggested as major risk factors for
DHF/DSS. In particular, two sequential infections, with the second
infection caused bya DENVserotypedifferent from the first, isa risk
factorforseverediseaseinchildrenandadults[2–5].Aprocesscalled
antibody dependent enhancement of infection (ADE), coupled with
strong anamnestic cellular immune responses is the leading
hypothesis to mechanistically explain more severe disease in
secondary infections [6–9]. Severe dengue can also occur in primary
infection of infants bornto dengue-immune mothers with, indicating
anamnestic immune responses are not absolutely critical for eliciting
the capillary permeability syndrome in all patients. Viral traits may
also be important in pathogenesis, with strong evidence that some
viral genotypes are fitter than others [10,11].
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plasma/serum viral burden, disease severity and immune status
generally supports the hypothesis that there is a positive
correlation between markers of viral burden in the first 2–3 days
of fever and the severity of clinical outcomes. For example, during
the febrile and early convalescent periods, Taiwanese adults with
secondary DENV-3 infections and DHF had higher plasma levels
of viral RNA than did patients with DF [12]. An association
between higher peak viremia and increased disease severity was
observed in Thai children with acute DENV-1 and -2 infections
[13]. Similarly, DHF was associated with higher plasma viremia
early in illness in Thai children with secondary DENV-3 infections
[14]. Duyen et al recently showed that DENV-1 infections were
associated with higher viremia and NS1 antigenemia than DENV-
2 infections in ambulatory Vietnamese paediatric patients [15]. In
the same patients, viremia and NS1 antigenemia persisted for
longer in patients with primary infections.
In adults, where the risk of clinically apparent disease occurring
in primary infection is possibly greater [16,17], there is less
evidence relating virological features of infection to immune status
or clinical outcome. Kuberski et al reported in 1977 that the
magnitude of viremia in young adult patients was higher in
primary than secondary DENV-1 infections [18]. More recently,
DENV viremia levels from Taiwanese adult patients were reported
to be lower in secondary than in primary DENV-2 infections [19].
The dynamics of virus clearance might also be relevant to
clinical outcome. In Thai children, Vaughn and others have
shown that the slope of the descending portion of the viremia
curve was steeper for patients with secondary infection versus
those with primary infection and viremia decreased more quickly
for patients with DHF than for patients with DF at defervescence
[13]. The accelerated clearance of viremia in secondary infection
most likely reflects the contribution of anamnestic humoral and
cellular immune responses, which themselves have been implicat-
ed in the pathogenesis of capillary leakage. Conversely however,
Wang et al suggested clearance of the virus and virus-containing
immune complexes was slower in adult DHF patients [20].
A better understanding of the relationship between biomarkers
of virus infection, the immune response and disease evolution is
critical for the rational use of intervention therapies in dengue, e.g.
anti-viral drugs or immune-modulating therapies. To this end, this
study describes the kinetics of viremia and NS1 in an intensively
investigated cohort of Vietnamese adults with dengue and less
than 72 hrs of fever enrolled in a randomized placebo-controlled
trial (RCT).
Methods
Study setting, participants and ethical considerations
A double blind RCT of chloroquine (CQ) in 307 adults
hospitalized for suspected DENV infection was conducted at the
Hospital for Tropical Diseases (Ho Chi Minh City, Vietnam)
between May 2007 and July 2008. Information on recruitment,
inclusion criteria, randomization, treatment and investigations
have been published previously [21]. The Scientific and Ethical
committee of the HTD and the Oxford Tropical Research Ethical
Committee approved the study protocol and all patients gave
written informed consent. The trial was registered with the
ISRCTN Register (ISRCTN38002730). Herein we describe the
clinical and virological features of the 257 patients with laboratory
confirmed dengue enrolled into this trial, which hitherto have not
been described in detail.
Dengue diagnostics and detection of DENV RNA and NS1
in plasma
A diagnosis of laboratory confirmed dengue was reached using
serological, antigen detection and molecular methods [22]. In
brief, RT-PCR detection of DENV RNA in plasma was
performed using an internally controlled, serotype-specific, real-
time RT-PCR TaqMan assay that has been described previously
[23]. RNA extraction from plasma samples was automated
(NucliSens easyMAG, BioMerieux, Lyon, France). Results were
expressed as cDNA equivalents per mL of plasma. A capture IgM
and IgG ELISA (MAC and GAC ELISA) using DENV/JEV
antigens and mAb reagents provided by Venture Technologies
(Sarawak, Malaysia), was performed as previously described [24].
NS1 was detected by using the NS1 Platelia ELISA assay from
BioRad (Hercules, CA) according to the manufacturer’s instruc-
tions. Samples defined as equivocal in the NS1 Platelia ELISA
assay were repeated and if they were still equivocal they were
regarded as being negative.
Host immune status
The interpretation of primary and secondary serological
responses was based on the magnitude of IgG ELISA units in
early convalescent plasma samples taking into account the illness
day. The cut-off in IgG ELISA units for distinguishing primary
from secondary dengue by illness day was calibrated using a panel
of acute and early convalescent sera from Vietnamese dengue
patients that were assayed at the Centre for Vaccine Development,
Mahidol University, Bangkok, Thailand using a reference IgM
and IgG antibody capture ELISA described previously [25].
Clinical and laboratory investigations
Clinical history and examination findings were recorded daily
into case record forms. An ultrasound was performed in all
patients within 24 hrs of defervescence. Venous blood samples
were collected at hospital admission, then twice daily (around 9am
and 3pm) for a minimum of 5 days after hospital admission and
again 10–14 days after discharge from the hospital. A complete
blood count, including hematocrit (Hct) and platelet measure-
ments, was performed daily for all patients. Hct measurements
were performed more frequently if clinically indicated. The extent
Author Summary
Dengue is an acute viral disease that affects tens of
millions of people annually in tropical and sub-tropical
countries. In some cases, this infection happens to be
severe and even life threatening. Severe cases have been
associated with higher levels of virus in the blood. Several
hypotheses have been proposed to explain the occurrence
of these cases notably by involving the patient’s history of
previous DEN virus infection(s). Little is known about the
relationships between the evolution over time of virus
levels in the blood, the clinical outcome and the previous
infection(s) history—a better understanding of these
features could help in anti-viral drug development. To
analyze these relationships, we studied well characterized
patients who participated in a clinical trial. The majority of
these patients were infected by DENV-1 serotype and had
higher levels of virus than those infected by DENV-2 and
sometimes DENV-3 serotypes. We also found that patients
with more severe symptoms had higher levels of virus in
the first days of their illness. We found as well that the
virus was cleared faster and earlier from the blood of
patients previously infected. These findings are of major
importance for further anti-viral drug testing.
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by comparing the maximum Hct recorded during hospitalization
with either the value recorded at follow-up when available (191/
248 i.e. 77% of the patients) or against a sex- and age-matched
population value. Plasma was stored frozen in multiple aliquots at
280uC until use in the real-time RT-PCR and NS1 ELISA. The
day of fever onset was self-reported by the patient and was
designated illness day 1.
Case definition
DF and DHF were diagnosed according to 1997 World Health
Organization (WHO) classification criteria and was applied to
each case after review of study notes [26]. The 1997 definitions
were used for this study because at the time of clinical assessment
the 2009 WHO Guidelines and revised classification scheme was
not available. DF was defined as a laboratory confirmed dengue
case with no evidence of capillary permeability as defined for a
DHF case. DHF was defined as laboratory confirmed dengue case
with thrombocytopenia (,100,000 platelets/mm3), any hemor-
rhagic manifestation, and evidence of plasma leakage (as denoted
by a .20% increase in the Hct from the baseline value or by the
presence of pleural or abdominal effusions).
Analysis and statistics
The data used in this analysis was taken from a randomised
controlled treatmenttrial ofdengue.Sincetheintervention(CQ) had
no measurable impact on virological or immunological outcomes,
for the purposes of this analysis we did not distinguish between
patients in the CQ or placebo arms of the study. All statistical
analysis was performed and figures designed using the software R
(version 2.10.1). Significance was assigned at P,0.05 and were two-
sided unless otherwise indicated. Uncertainty was expressed by 95%
confidence intervals. The Kruskal-Wallis rank sum test was used for
continuous variables and the Fisher’s exact test for categorical
variables. Forthe viremia kinetics analysis,whenthe RT-PCRsignal
was below the assay limit of detection (defined as the last dilution of
standardthatgaveaspecificsignal),avalueequaltoconcentration of
the last dilution of standard that gave a specific signal divided by 10
was assigned. The maximum viremia level was defined asthe highest
plasma viremia level measured during illness. The maximum
viremia level was considered to be a peak viremia level only in
cases in which viremia rose after the enrolment specimen. To
compare kinetics of viremia between patients with different
serological status, disease severity and serotype, the means of log-
transformed viremia measurements made on the same illness day
were used as a summary measure of the viremia on that day. To
estimate the maximum daily rate of DENV clearance, the slope of
the viremia curve was calculated for each illness day as the change in
the means of log-transformed viremia measurements made on the
same illness day. Only the maximum decreasing daily rate of each
patient was used for analysis. Survival analysis using the Kaplan-
Meier method and log-rank test was used for all time-to-event
outcomes. Time to resolution of viremia or NS1 antigenemia was
defined as the time from the start of symptoms until the first of two
consecutive plasma samples below the RT-PCR limit of detection or
NS1 ELISA negative.The feverclearancetime(FCT)was defined as
the time from the start of symptoms to the start of the first 48 hours
period during which axillary temperature remained below 37.5uC.
Results
Characteristics of the study population
Of the 307 adults with suspected dengue enrolled in the CQ
RCT between May 2007 and July 2008, 257 had laboratory-
confirmed dengue including 248 patients with a defined serological
and clinical classification and 9 patients with ambiguous or
unknown clinical outcomes or serology (mainly because they left
the study prematurely). The characteristics of the study population
are summarized in Table 1 (and Table S1). DENV-1 (57.3%) was
the commonest serotype detected in this population of patients,
then DENV-2 (20.6%), DENV-3 (15.7%) and DENV-4 (2.8%).
DHF was significantly associated with secondary infection com-
pared with primary infection (65/215 vs 4/33 i.e. 30.2% vs 12.1%,
P=0.04, Odds ratio (OR)=3.13, 95% CI 1.04–12.75). DHF
resulting from secondary infection was more commonly associated
with DENV-2 (21/45 (46.7%)) than for other serotypes (DENV-1:
33/124 (26.6%), DENV-3: 10/33 (30.3%) and DENV-4: 1/7
(14.3%) (DENV-2 vs DENV-1, -3 and -4 P=0.02, OR=2.38,
95% CI 1.14–4.96) (Table S1).
Viremia kinetics in DF and DHF according to serological
status
Median viremia levels by illness day for DENV-1, -2 and -3 are
shown in Figure 1 (and Table S2). In DF patients with primary
infection, DENV-1 viremia levels were significantly higher than
DENV-2 or DENV-3 levels at multiple time-points during the
acute illness (Figure 1A). In DF patients with secondary infection,
the most common serological and clinical grouping, and DHF
patients with secondary infection, DENV-1 levels were signifi-
cantly higher than DENV-2 levels and there was also a non-
significant trend towards higher DENV-1 levels than DENV-3
levels (Figure 1B and C). Collectively, and despite small sample
sizes for some subgroups, these data suggest that DENV-1
infections were associated with higher viremias (as measured by
qRT-PCR) than DENV-2, irrespective of disease severity and
immune status.
DENV-1 was the commonest serotype detected in this patient
population and therefore there was sufficient data to enable direct
comparisons of viremia kinetics across serological states and
clinical severity whilst controlling for the infecting serotype (Table
S2). These data show that in the early acute phase (illness day 3)
patients with DENV-1 infection and DHF had significantly higher
viremia levels than DENV-1 patients with DF, irrespective of the
patient immune status (Figure 2). These data show also that later
in the acute phase (from day 4 of illness) patients with primary
DENV-1 infections had significantly higher viremia levels than
patients with secondary DENV-1 infections, irrespective of the
disease severity (Figure 2).
A limitation of these analyses is that in the majority of patients
with secondary infections the viremia was already declining at the
time of enrolment i.e. we did not observe an obvious peak viremia
(Table S3). Overall, a peak viremia was significantly less often
observed in secondary infections than in primary infections for all
disease severity grades (P=0.001, OR=3.64, 95% CI 1.55–8.74).
However, there were no significant differences in the duration of
illness prior to enrolment between patients in different categories
of serological status or disease severity (P between 0.11 and 0.96 if
all the serotypes are considered, and 0.16 and 0.39 if and only
DENV-1), suggesting this snapshot of viremia levels is unbiased by
differences in duration of illness at study enrolment.
Timing and amplitude of peak viremia and associations
with severity and immune status
Peak viremia levels were identified in 72 patients. Peak viremia
occurred significantly earlier in secondary DF than in primary DF
(P=0.008) and in secondary DHF than in primary DHF (P=0.04)
but there were no significant differences between primary DF and
Virus Kinetics in Adults with Dengue
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secondary DHF (P=0.13) for the peak viremia time (Table S3).
Amongst DENV-1 infected patients, peak viremia levels, when
observed (in 51 of 142 DENV-1 infected patients), happened
significantly earlier in secondary DF than in primary DF
(P=0.0006) but, possibly because of small sample size, not in
secondary DHF compared to primary DHF (P=0.31). There was
no significant difference between secondary DF and secondary
DHF (p=0.48) but there was a non-significant trend towards later
viremia peaks in primary DF than in primary DHF (P=0.052).
There were sufficient observations of the magnitude of peak
viremia in DENV-1 infections to look for associations with clinical
outcome in this subgroup (Table S3). Peaks of viremia were
observed in 9 primary DF, 29 secondary DF, 3 primary DHF and
10 secondary DHF DENV-1 infected patients. Peak viremia levels
were not significantly different between DF and DHF patients (DF
vs DHF log10 median peak levels 9.89 vs 10.27, P=0.28) but
there was a non-significant trend towards higher peak viremia
during secondary infections than primary infections (primary vs
secondary P=0.096 and primary DF vs secondary DF P=0.086).
If considering the highest viremia levels (as distinct from peak
viremia levels) in DENV-1 patients, these were significantly higher
in DHF than in DF (log10 median levels 9.84 vs 9.19, P=0.03).
Because most DHF cases were associated with secondary
infections, for which peak viremia had already past by the time
of enrolment, this difference is probably underestimated. These
results suggest secondary infections are generally associated with
earlier peak viremia but do not provide any conclusive evidence of
higher peak viremia levels in DHF and/or secondary infections.
Maximum daily rate of virus clearance
In the 239 patients with detectable viremia, the median of
maximum daily rates of DENV clearance (estimated as the slope of
the steepest descending daily portion of the viremia curve) was 2.2
log10 per day in primary DF, 2.8 log10 per day in secondary DF,
2.1 log10 per day in primary DHF and 3.0 log10 per day in
secondary DHF. The maximum daily rate of clearance was
significantly higher in patients with secondary infections (median
of the maximum daily loss 2.9 logs per day) versus those who
experienced primary infections (median of maximum daily
losses=2.1 logs per day, P,0.00001) (primary DF vs secondary
DF P=0.00004 and primary DHF vs secondary DHF P=0.025).
The results were very similar when considering only DENV-1
patients for analysis (data not shown). These data suggest
secondary infection is associated with steeper declines in viremia.
Time to resolution of viremia in DF and DHF according to
serological status
Amongst all viremic patients (n=239) time to resolution of
viremia was significantly longer in primary infections than in
secondary infections (hazard ratio (HR)=2.88, 95% CI 1.79–4.63,
log rank test P=0.000005), in primary DF than in secondary DF
(HR=2.60, 95% CI 1.57–4.32, log rank test P=0.0001) and in
primary DHF than in secondary DHF (HR=4.92, 95% CI 1.19–
20.32, log rank test P=0.015) (Figure 3A). Median times to
resolution of dengue viremia were 148 hrs (IQR 140–173 hrs) in
primary DF, 162 hrs (134–.171 hrs) in primary DHF, 120 hrs
(97–141.5 hrs) hrs in secondary DF and 123 hrs (113–138 hrs) in
secondary DHF.
Amongst DENV-1 infected patients only (n=142), times to
resolution of viremia were also significantly longer in primary
infections than in secondary infections (HR=4.21, 95% CI 2.12–
8.35, log rank test P=0.000009), in primary DF than in secondary
DF (HR=3.67, 95% CI 1.76–7.62, log rank test P=0.0002) and
in primary DHF than in secondary DHF (HR=7.00, 95% CI
0.94–52.17, log rank test P=0.03) (Figure 3B). Median times to
Table 1. The characteristics of the study population
a.
N (%) or Median (interquartile range)
Variables Primary (N=33) Secondary (N=215)
Age (years) 19 (17–25) 22 (18–27)
Male sex 20 (60.6%) 147 (68.4%)
Viremic 30 (90.9%) 209 (97.2%)
Infecting serotype:
DENV-1 18 (60.0%) 124 (59.3%)
DENV-2 6 (20.0%) 45 (21.5%)
DENV-3 6 (20.0%) 33 (15.8%)
DENV-4 0 (0.0%) 7 (3.4%)
NS1 ELISA positive 28 (84.8%) 186 (86.5%)
Febrile 31 (93.9%) 209 (97.2%)
Time since illness onset (hrs) 51.5 (43.5–68.0) 49.0 (41.3–55.0)
Disease severity:
DF 29 (87.9%) 150 (69.8%)
DHF 4 (12.1%) 65 (30.2%)
Treatment allocation by disease severity
b: CQ Placebo CQ Placebo
DF 19 (65.5%) 10 (34.5%) 78 (52.0%) 72 (48.0%)
DHF 2 (50.0%) 2 (50.0%) 27 (41.5%) 38 (58.5%)
aWere omitted from this table 9 patients with ambiguous or unknown clinical outcomes or serology (mainly because they left the study prematurely).
bPercentages given here are within the same group of immune status and disease severity.
doi:10.1371/journal.pntd.0001309.t001
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in primary DF, .171.1 hrs (134–.179 hrs) in primary DHF
(since less than 50% of primary DHF had cleared viremia before
discharge), 125 hrs (99–150 hrs) in secondary DF and 127 hrs
(107–143.5) in secondary DHF.
Time to resolution of NS1 antigenemia in DF and DHF
according to serological status
Of the 248 patients with defined serological and clinical
classifications, there were 214 patients NS1 positive at the time
of study enrolment (plus 2 patients negative at enrolment but NS1
positive 24 and 42 hrs later). Consistent with the viremia findings,
times to resolution of NS1 antigenemia were significantly longer in
primary infections than in secondary infections (HR=4.57, 95%
CI 2.01–10.40, log rank test P=0.00007), in primary DF than in
secondary DF (HR=3.66, 95% CI 1.47–9.07, log rank test
P=0.003), in primary DHF than in secondary DHF (HR=7.04,
95% CI 0.97–51.15, log rank test P=0.02) but also in secondary
DF than in secondary DHF (HR=1.86, 95% CI 1.29–2.67, log
rank test P=0.0007) (Figure 4A). Interestingly, only 5 of 25
patients (i.e. 20%) with primary DF and 1 of 4 patients (i.e. 25%)
with primary DHF had cleared NS1 when discharged from
hospital. In patients with secondary dengue, 69 of 127 with
secondary DF (i.e. 54.3%) and 51 of 60 with secondary DHF (i.e.
85%) had cleared NS1 when discharged from hospital. Median
times to resolution of NS1 antigenemia since illness onset were
Figure 1. Magnitude of DENV viremia by illness day. Levels of
DENV-1, -2, -3 and -4 genome equivalent cDNA copies per millilitre were
determined in serial plasma samples from patients with A) primary DF
(n=26), B) secondary DF (n=144) and C) secondary DHF (n=64). Data
are median and IQR. *** P,0.001 ** 0.001,P,0.01 * 0.01,P,0.05 t
0.05,P,0.1. Data from patients with DENV-1 and -2 primary DHF (n=3
and n=1 respectively) and DENV-4 secondary DHF (n=1) are not
displayed because the number of these patients was too small for
statistical analysis. The numbers below the graph indicate the numbers
of patients at each time point. The dashed line represents the assay
limit of detection.
doi:10.1371/journal.pntd.0001309.g001
Figure 2. Magnitude of DENV-1 viremia by illness day. Levels of
DENV-1 genome equivalent cDNA copies per millilitre were determined
in serial plasma samples from DENV-1 infected patients with primary DF
(n=15), primary DHF (n=3), secondary DF (n=91) and secondary DHF
(n=33). Data are median and IQR. *** P,0.001 ** 0.001,P,0.01
* 0.01,P,0.05 t 0.05,P,0.1. The numbers below the graph indicate
the numbers of patients at each time point (2 per patient for most of
the time points). The dashed line represents the assay limit of detection.
doi:10.1371/journal.pntd.0001309.g002
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.171 hrs) in primary DHF (since less than 50% of primary DF
and primary DHF had cleared NS1 before discharge), and 137 hrs
(105–.174 hrs) in secondary DF and 121 hrs (100–153 hrs) in
secondary DHF.
Amongst DENV-1 infected patients (n=142), 134 were NS1
positive at the time of study enrolment. Times to resolution of NS1
antigenemia were significantly longer in DENV-1 primary
infections than in DENV-1 secondary infections (HR=not
applicable, log rank test P=0.00008), in DENV-1 primary DF
than in DENV-1 secondary DF (HR=3.66, 95% CI 1.47–9.07,
log rank test P=0.003), in DENV-1 primary DHF than in DENV-
1 secondary DHF (HR=7.04, 95% CI 0.97–51.15, log rank test
P=0.004) and in DENV-1 secondary DF than in DENV-1
secondary DHF (HR=1.86, 95% CI 1.29–2.67, log rank test
P=0.00001) (Figure 4B). Strikingly, none of the DENV-1 infected
patients with primary DF (n=15) or primary DHF (n=3) had
cleared NS1 when they were discharged from hospital. In contrast,
36 of 84 (42.9%) secondary DF and 29 of 31 (93.5%) secondary
DHF patients had cleared NS1 when they were discharged.
Median times to resolution of NS1 antigenemia since illness onset
were .172.5 hrs in primary DF, .171 hrs in primary DHF,
Figure 3. Time to resolution of DENV viremia. Kaplan-Meyer survival analysis of time to resolution of plasma viremia in all viremic A) or DENV-1
only B) patients.
doi:10.1371/journal.pntd.0001309.g003
Figure 4. Time to resolution of NS1 antigenemia. Kaplan-Meyer survival analysis of time to resolution of NS1 antigenemia in all viremic A)o r
DENV-1 only B) patients. Two patients NS1 negative at enrolment were later positive and for the purposes of analysis were considered positive at the
time of enrolment.
doi:10.1371/journal.pntd.0001309.g004
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secondary DF, and primary DHF had cleared NS1 before
discharge) and 121 hrs (103–144 hrs) in secondary DHF.
Collectively, these results suggest that DENV infection is cleared
earlier and faster in secondary infections than in primary
infections.
Fever clearance time in DF and DHF according to
serological status
There were 240 patients febrile at enrolment (plus 2 afebrile
patients who developed fever soon after). Overall, FCT were
significantly longer in primary infections than in secondary
infections (log rank test P=0.037) but there was no significant
difference between primary DF and secondary DF (HR=1.44,
95% CI 0.93–2.23, log rank test P=0.096), and between primary
DHF and secondary DHF (HR=1.85, 95% CI 0.67–5.14, log
rank test P=0.23) (Figure 5). Median FCT since illness onset was
131 hrs (IQR 95.5–151.4 hrs) in primary DF, 141 hrs (135.5–
160.5 hrs) in primary DHF, 118 hrs (93.1–140.2 hrs) in secondary
DF and 120 hrs (105–142 hrs) in secondary DHF. Consistent with
the viremia and NS1 findings, these data indicate primary
infection was associated with a longer-lived febrile period.
DENV-1 viremia kinetics and associations with
haematological parameters
For descriptive purposes, the evolution over time of DENV-1
viremia in the context of white blood cell and platelet counts and
percentage hemoconcentration was plotted (Figure 6) and
summarised in Table S4. The highest levels of hemoconcentration
and the lowest platelet counts occur when the viremia is close to
resolution and when the patient is already or very nearly afebrile.
The time to platelet nadir and maximum hemoconcentration was
shorter in secondary DENV-1 infections (P,0.01). The data also
suggest that leucopenia lasts longer in primary infections than in
secondary infections.
Discussion
The interplay between DEN virus infection and host immune
status is postulated to play a central role in the pathophysiology of
severe dengue. In this current study, we observed important
features of this dynamic. First, early viremia levels were higher in
patients with DHF, even if the peak viremia level was often not
observed because it occurred prior to enrolment. Second, DENV-
1 infections manifested as higher and longer-lived viremias,
suggesting serotype dependent differences in infection kinetics.
Third, the clearance of DENV viremia and NS1 antigenemia
occurs earlier and faster in patients with secondary dengue and is
also consistent with a faster time to defervescence.
Our findings are in agreement with previous studies that found
higher viremias associated with more severe disease [12–14]. Our
data also suggests that quantitative differences exist between
DENV serotypes with respect to the kinetics of viremia and NS1
antigenemia. In particular, DENV-1 infections were associated
with higher and frequently longer-lived viremia levels than
infections with either DENV-2 or DENV-3. This is in agreement
with recent observations in Vietnamese children and adults
[15,27]. DENV-2 was associated with secondary infection and
severe disease in our study; this is also in accordance with previous
studies [2,27,28]. The mechanisms that facilitate relatively higher
viremia in DENV-1 infections relative to DENV-2 infections in
our study population, and also recently in Vietnamese children
[15], are unknown. Plausibly, DENV-1 has an intrinsically faster
rate of replication in this patient population and thereby attains a
higher infected cell mass in vivo than DENV-2. Clearly, further
studies will be needed to explore this.
The duration of NS1 antigenemia was shorter in patients with
secondary infections and this is consistent with previous studies
that have suggested reduced sensitivity of NS1-based diagnostic
tests in patients with secondary infections [22,29–32]. One
explanation is that NS1 is less likely to be available for detection
when a sufficient level of DENV-reactive IgG (including anti-NS1
IgG) develops during secondary infections. This may serve to mask
the antigen from detection in the immunoassay, and/or result in
rapid clearance of NS1 in the form of immune-complexes.
Secondary dengue is associated with faster resolution of viremia
infection and shorter duration of fever. Interestingly, the daily
rates of virus clearance observed in our study were very
compatible with those found by Vaughn et al in Thai children
[13]. The early adaptive immune response during secondary
infection is dominated by populations of memory B and T cells
(and possibly memory-like NK cells [33]) and at least some
components of this response mediate a strong anti-viral action, as
evidence by faster clearance rates of the viremia and the NS1
antigenemia. Clearly however, aspects of this rapid host immune
response are clinically deleterious given the epidemiological
association between secondary dengue and more severe outcomes,
and also the timing of when clinical manifestations of capillary
permeability occur. This poses the intriguing question of whether
modulating the host immune response (e.g. through early
corticosteroid therapy) could achieve both a more gradual
clearance of the virus and a host immune response that elicits
less pathology.
Assuming blood viremia is a reasonable surrogate of the whole-
bodyvirus burden, then the rapid decline of viremia 48–72 hrs after
illness onset, especially in secondary infections that carry higher risk
for severe outcomes, has implications for rational design of
therapeutic pharmacological interventions. An efficacious anti-viral
will need favourable pharmacokinetic properties and potency if it is
to impact on the viral burden in a rapid and clinically significant
Figure 5. Fever clearance time. Kaplan-Meyer survival analysis of
fever clearance time in all viremic patients. Two patients afebrile at
enrolment developed fever soon after and for the purposes of analysis
were considered febrile at the time of enrolment.
doi:10.1371/journal.pntd.0001309.g005
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host immune response, which accounts for the rapid decline of
viremia but which also likely contributes to the capillary
permeability syndrome, may equally need to be administered early
on in illness e.g. in a prophylactic way, to prevent clinical
complications such as DSS. The rapid decline in viremia in
secondary infections also highlights the importance of early
diagnosis, since early diagnosis will provide the greatest opportunity
for an intervention (e.g. an anti-viral), to have an impact. Point of
care NS1diagnostics areavailablebutmore canbe done to improve
their sensitivity [34]. More clinical research is also needed to
understand if the sensitivity and specificity of early clinical diagnoses
(and prognosis)canbe improved,particularlyinprimaryhealth care
settings. Recent literature suggests this is feasible [35,36].
Current animal models of DENV infection are able to provide
for in vivo measurements of anti-viral activity [37,38]. However
these models do not reproduce the temporal changes in virological
biomarkers and clinical manifestations seen in naturally infected
dengue patients. The lack of concordance between virological and
clinical events in small animal models, and what occurs in patients,
needs to be carefully considered when evaluating candidate anti-
viral drugs for dengue. For instance, the onset of vascular
permeability does not follow the disappearance of virus during
enhanced DENV infection in mouse models [38,39].
There are several limitations to our study. Our results are
derived from hospitalized patients who are not necessarily
representative of patients being seen at the primary health care
level. Interestingly however, the same themes identified in this
study in hospitalized Vietnamese adults were also observed in
Vietnamese children presenting to primary health care level clinics
in Ho Chi Minh City [15]. Of the 248 patients in this study with a
defined serological and clinical classification, 126 received a 3 day
Figure 6. Profile of haematological parameters and viremia in DENV-1 infected patients. Medians of viremia levels, WBC and platelet
counts, hemoconcentration, and percentages of lymphocytes and neutrophils were determined in serial plasma samples from DENV-1 infected
patients with A) primary DF, B) secondary DF, C) primary DHF and D) secondary DHF. The numbers below the graph indicate the numbers of patients
at each time point. For reasons of clarity, error bars are not shown.
doi:10.1371/journal.pntd.0001309.g006
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were detected, an effect of CQ on the clinical phenotype cannot be
excluded because vomiting was more frequent in this treatment
arm, possibly leading to more dehydration [21]. The majority of
the patients in this study were infected by DENV-1. Very few had
primary DHF (4 of 248). RT-PCR measurements of viremia in
plasma may not be an entirely accurate surrogate of the infected
cell mass in vivo, although it is certainly a better surrogate than
NS1 antigenemia, which persists well after the febrile period and is
heavily influenced by the immune status of the host (i.e. primary
versus secondary). Viremia measurements assessed by RT-PCR
encompass both infectious and non-infectious viral particles, and
the relative proportions may vary between the different serological
responses and/or serotypes [40]. Assessment of plasma virus titers
based on plaque titration would have been a valid alternative
approach to measuring virus concentrations in plasma, however
this biological assay is more difficult to standardize and validate
relative to a RT-PCR assay. Another general limitation of
measuring virus concentrations in plasma is that viruses might
be sequestered in other tissues but inaccessible to measurement
while still playing a role in disease pathogenesis.
Our study emphasizes the importance of the period before and
just after the onset of fever. This and other studies have established
that early viremia levels are associated with disease severity,
although they are very clearly not the only determinant of
outcome. Very little is known of the virological events in the hours
preceding and shortly after fever onset, mainly because this is very
difficult to investigate without a good experimental model. An
interesting insight was provided by clinical trials of DENV-1, -3
and -4 monovalent live attenuated vaccines in the 1980s [41–43].
These vaccines were not sufficiently attenuated and some
volunteers developed dengue fever. These studies suggest that
viremic period starts several days before the onset of symptoms
This presymptomatic viremic period should not be underestimated
because of its possible contribution to DENV transmission to
uninfected mosquitoes. In our study, we also observed prolonged
times of virus clearance in primary dengue, and long-lived higher
viremia levels in DENV-1 infections. These might lead to a higher
possibility of human to mosquito virus transmission by maintain-
ing viremia above the infectious level over a longer period of time.
Collectively, our findings reveal important patterns of the
viremia and NS1 antigenemia kinetics according to the patient
immune response, disease severity and virus serotype, and may
help for the rational design of clinical trials of therapeutic
interventions, especially antivirals.
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